A. Traynor

发表

Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial

H. Wakelee, D. Gandara, S. Ramalingam, 2017, The Lancet. Oncology.

Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer.

Pranshu Mohindra, Deepak Khuntia, Søren M Bentzen, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors

W. Read, G. Wilding, M. Gordon, 2010, Investigational New Drugs.

Comprehensive IMRT plus weekly cisplatin for advanced head and neck cancer: The University of Wisconsin experience

P. Harari, S. Bentzen, J. Cleary, 2009, Head & neck.

Quantitative FDG PET/CT may help risk-stratify early-stage non-small cell lung cancer patients at risk for recurrence following anatomic resection.

R. Jeraj, S. Harmon, C. Seder, 2019, Journal of thoracic disease.

Ifosfamide, carboplatin and etoposide combined with 41.8 degrees C whole body hyperthermia for malignant pleural mesothelioma.

U. Gatzemeier, I. Bruns, K. Dalhoff, 2003, Lung cancer.

Ifosfamide, carboplatin and etoposide combined with 41.8 °C whole body hyperthermia for malignant pleural mesothelioma

U. Gatzemeier, I. Bruns, K. Dalhoff, 2003 .

Myosteatosis as a Shared Biomarker for Sarcopenia and Cachexia Using MRI and Ultrasound

S. Reeder, T. Campbell, D. Tamada, 2022, Frontiers in Rehabilitation Sciences.

A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies

G. Wilding, J. Kolesar, J. Eickhoff, 2013, Investigational New Drugs.

Increased local failure risk with prolonged radiation treatment time in head and neck cancer treated with concurrent chemotherapy

P. Harari, T. McCulloch, H. Geye, 2014, Head & neck.

A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer

G. Wilding, J. Kolesar, K. Wisinski, 2015, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer.

R. Kaiser, R. Doebele, D. Camidge, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies

G. Wilding, J. Eickhoff, A. Tevaarwerk, 2009, Cancer Chemotherapy and Pharmacology.

A phase I study of Triapine® in combination with doxorubicin in patients with advanced solid tumors

G. Wilding, J. Kolesar, J. Eickhoff, 2009, Cancer Chemotherapy and Pharmacology.

A phase II trial of Triapine® (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503

J. Kolesar, J. Schiller, M. Mazurczak, 2010, Investigational New Drugs.

Phase 1 trial of bevacizumab with concurrent chemoradiation therapy for squamous cell carcinoma of the head and neck with exploratory functional imaging of tumor hypoxia, proliferation, and perfusion.

R. Jeraj, P. Harari, T. McCulloch, 2015, International journal of radiation oncology, biology, physics.

Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study

KyungMann Kim, J. Eickhoff, R. Go, 2016, British journal of haematology.

Applications in Head and Neck Cancer

P. Harari, D. Khuntia, A. Traynor, 2006 .

A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501

N. Hanna, D. Carbone, J. Schiller, 2008 .

Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer.

J. Soria, V. Papadimitrakopoulou, B. Johnson, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study

J. Kolesar, KyungMann Kim, T. Campbell, 2014, Investigational New Drugs.

Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study.

M. Burkard, KyungMann Kim, A. Tevaarwerk, 2014, Clinical Breast Cancer.

Abstract P3-12-10: Feasibility of four cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: A Wisconsin oncology network study

M. Burkard, KyungMann Kim, A. Tevaarwerk, 2013 .

Aminoglycoside dosing weight correction factors for patients of various body sizes

A. Traynor, A. Nafziger, J. Bertino, 1995, Antimicrobial agents and chemotherapy.

Initial clinical experience with stereotactic lung radiotherapy, based on a biological model-driven prescription method.

M. Mehta, W. Tomé, T. Weigel, 2011, Journal of radiosurgery and SBRT.

E1505: Adjuvant chemotherapy +/- bevacizumab for early stage NSCLC--Outcomes based on chemotherapy subsets.

H. Wakelee, D. Gandara, S. Ramalingam, 2016 .

Phase I Study of Sunitinib and Erlotinib in Advanced Nonsquamous Non-small Cell Lung Cancer

KyungMann Kim, T. Campbell, S. Seo, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

VcR‐CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study

KyungMann Kim, N. Callander, David T Yang, 2018, Clinical lymphoma, myeloma & leukemia.

An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer.

Jesse S. Voss, B. Goh, R. Smallridge, 2020, Thyroid : official journal of the American Thyroid Association.

Clinical Imaging and Dosimetry of a Pan-Cancer Targeting Alkylphosphocholine Analog, [124I]I-NM404

Steve Y. Cho, B. Bednarz, J. Kuo, 2022, Radiation.

Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies

G. Wilding, T. Mody, H. Bailey, 2011, Investigational New Drugs.

Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes

G. Wilding, J. Kolesar, KyungMann Kim, 2013, Cancer Chemotherapy and Pharmacology.

Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PF-00337210, a highly selective VEGFR inhibitor.

P. LoRusso, D. Shalinsky, A. Ricart, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Systemic treatment of advanced non-small cell lung cancer.

J. Schiller, A. Traynor, 2004, Drugs of today.

Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC).

J. Soria, V. Papadimitrakopoulou, A. Jappe, 2010 .

Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients

G. Wilding, J. Kolesar, R. Brundage, 2011, Cancer Chemotherapy and Pharmacology.

Cytotoxic Evaluation of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, 3-AP, in Peripheral Blood Lymphocytes of Patients with Refractory Solid Tumors using Electron Paramagnetic Resonance.

G. Wilding, J. Kolesar, J. Eickhoff, 2011, Experimental and therapeutic medicine.

Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with Triapine.

G. Wilding, J. Kolesar, W. Antholine, 2008, Journal of inorganic biochemistry.

A Double-Blind Randomized Discontinuation Phase-II Study of Sorafenib (BAY 43–9006) in Previously Treated Non–Small-Cell Lung Cancer Patients: Eastern Cooperative Oncology Group Study E2501

N. Hanna, H. Wakelee, D. Carbone, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors

Jason Clark, K. Flaherty, G. Wilding, 2011, Cancer Chemotherapy and Pharmacology.

Alkylphosphocholine Analogs for Broad-Spectrum Cancer Imaging and Therapy

P. Pickhardt, J. Kuo, Kyle Swanson, 2014, Science Translational Medicine.

A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer.

Andrea K. Kukla, B. Goh, R. Smallridge, 2012, The Journal of clinical endocrinology and metabolism.

Mutation and Polymorphism in the EGFR-TK Domain Associated with Lung Cancer

J. Siegfried, M. Romkes, J. Grandis, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Capecitabine and oxaliplatin in combination as first- or second-line therapy for metastatic breast cancer: a Wisconsin Oncology Network trial

A. Tevaarwerk, J. Stewart, U. O. Njiaju, 2013, Cancer Chemotherapy and Pharmacology.

Phase I/II Study of Gemcitabine and Exisulind as Second-Line Therapy in Patients with Advanced Non–small Cell Lung Cancer

T. Hensing, KyungMann Kim, J. Schiller, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer.

J. Siegfried, S. Dacic, J. Kolesar, 2009, Lung cancer.

Brigatinib in Patients with Alectinib-Refractory ALK-Positive Non-Small Cell Lung Cancer: A Retrospective Study.

S. Digumarthy, A. Shaw, B. Yeap, 2018 .

Non-small-cell lung cancer and breast carcinoma: chemotherapy and beyond.

J. Siegfried, A. Traynor, S. Dubey, 2006, The Lancet. Oncology.

Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer

J. Schiller, A. Traynor, 2006 .

Molecular Targeted Therapies in Head and Neck Cancer

P. Harari, V. Gondi, A. Traynor, 2011 .

Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study

L. Tye, Xin Huang, J. Schiller, 2009, Cancer Chemotherapy and Pharmacology.

Integrated Onco-Palliative Care Associated With Prolonged Survival Compared to Standard Care for Patients With Advanced Lung Cancer: A Retrospective Review.

J. Eickhoff, T. Campbell, A. Traynor, 2016, Journal of pain and symptom management.

The use of single-agent dasatinib in molecularly unselected non-small-cell lung cancer patients

D. Wheeler, T. Kruser, A. Traynor, 2011, Expert opinion on investigational drugs.

Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab

D. Wheeler, M. Iida, T. Brand, 2013, Cancer biology & therapy.

Novel therapies for lung cancer.

J. Schiller, A. Traynor, T. Hoang, 2002, Surgical oncology.

Metastasis of primary lung carcinoma to the breast: a systematic review of the literature.

Lonie R. Salkowski, L. Wilke, Jennifer A. Mirrielees, 2014, The Journal of surgical research.

Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study.

J. Eickhoff, A. Traynor, B. Kahl, 2014, Clinical advances in hematology & oncology : H&O.

Dose Escalated, Hypofractionated Radiotherapy Using Helical Tomotherapy for Inoperable Non-Small Cell Lung Cancer: Preliminary Results of a Risk-Stratified Phase I Dose Escalation Study

H Jaradat, S M Bentzen, W. Tomé, 2008, Technology in cancer research & treatment.

Vorinostat (NSC# 701852) in Patients with Relapsed Non-small Cell Lung Cancer: A Wisconsin Oncology Network Phase II Study

G. Wilding, J. Kolesar, J. Schiller, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Strategies to prevent brain metastasis in high-risk non-small-cell lung cancer: lessons learned from a randomized study of maintenance temozolomide versus observation.

M. Mehta, C. Langer, H. Robins, 2014, Clinical lung cancer.

Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.

C. Obasaju, P. Jänne, K. Kelly, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An eHealth system supporting palliative care for patients with non–small cell lung cancer

Ming-Yuan Chih, Kang Namkoong, David H Gustafson, 2013, Cancer.

A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer

J. Eickhoff, S. Lubner, A. Traynor, 2015, Cancer Chemotherapy and Pharmacology.

A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.

R. Smallridge, C. Erlichman, V. Suman, 2014, The Journal of clinical endocrinology and metabolism.

Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma

D. Ettinger, M. Mahoney, P. Fracasso, 2006, Cancer.

Phase I Dose‐Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors

D. Mutch, J. Wheler, A. Traynor, 2017, The oncologist.

A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B‐cell non‐Hodgkin lymphoma: A Wisconsin Oncology Network study

A. Onitilo, Kyungeun Kim, Sandeep Saha, 2015, Cancer.

Brigatinib in Patients With Alectinib‐Refractory ALK‐Positive NSCLC

S. Digumarthy, A. Shaw, B. Yeap, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase II study of vorinostat (NSC 701852 ) in patients (pts) with relapsed non-small cell lung cancer (NSCLC)

J. Kolesar, J. Schiller, J. Eickhoff, 2007 .

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.

B. Goh, R. Smallridge, Hui Tang, 2010, The Lancet. Oncology.

A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid tumors

E. Heath, P. LoRusso, E. Sadowski, 2016, Cancer Chemotherapy and Pharmacology.

Adjuvant therapy in the treatment of non-small-cell lung cancer.

J. Schiller, A. Traynor, 2002, Clinical lung cancer.

Phase I/II Study of Vinorelbine and Exisulind as First-Line Treatment of Advanced Non-small Cell Lung Cancer in Patients at Least 70 Years Old: A Wisconsin Oncology Network Study

KyungMann Kim, J. Schiller, G. Masters, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study

D. Deming, T. Goggins, S. Lubner, 2013, Investigational New Drugs.

Targeting Estrogen Receptor Beta in a Phase 2 Study of High-Dose Estradiol in Metastatic Triple-Negative Breast Cancer: A Wisconsin Oncology Network Study.

M. Burkard, KyungMann Kim, Wei Xu, 2016, Clinical breast cancer.

Feasibility report of image guided stereotactic body radiotherapy (IG-SBRT) with tomotherapy for early stage medically inoperable lung cancer using extreme hypofractionation

Anne Traynor, Deepak Khuntia, Wolfgang A Tomé, 2006, Acta oncologica.

A phase I dose-escalation and pharmacokinetic (PK) study of sunitinib (SU) plus docetaxel (D) in patients (pts) with advanced solid tumors (STs)

L. Tye, J. Schiller, A. Sandler, 2007 .

A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as ﬁ rst-line treatment in patients with advanced non-small-cell lung cancer

D. Camidge, G. Otterson, A. Traynor, 2022 .

A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer

J. Nieva, M. Schell, T. Owonikoko, 2016, The oncologist.

Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503).

J. Kolesar, J. Schiller, J. Brahmer, 2014, European journal of cancer.

A Phase I Pharmacokinetic and Pharmacodynamic Correlative Study of the Antisense Bcl-2 Oligonucleotide G3139, in Combination with Carboplatin and Paclitaxel, in Patients with Advanced Solid Tumors

D. McNeel, G. Wilding, J. Kolesar, 2008, Clinical Cancer Research.

A Phase I Pharmacokinetic and Pharmacodynamic Correlative Study of the Antisense Bcl-2 Oligonucleotide G3139, in Combination with Carboplatin and Paclitaxel, in Patients with Advanced Solid Tumors

D. McNeel, G. Wilding, J. Kolesar, 2008, Clinical Cancer Research.

Pharmacokinetic and Pharmacodynamic Correlative Study of theAntisense Bcl-2 Oligonucleotide G 3139 , in Combinationwith Carboplatin and Paclitaxel , in Patients with Advanced Solid Tumors

D. McNeel, G. Wilding, J. Kolesar, 2008 .

High Specificity in Circulating Tumor Cell Identification Is Required for Accurate Evaluation of Programmed Death-Ligand 1

D. Beebe, J. Lang, S. Berry, 2016, PloS one.

Paired diagnostic and pharmacodynamic analysis of rare non-small cell lung cancer cells enabled by the VerIFAST platform.

David J Beebe, Jacob J Tokar, Benjamin P Casavant, 2014, Lab on a chip.

Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors

G. Wilding, J. Kolesar, J. Eickhoff, 2009, Cancer Chemotherapy and Pharmacology.

Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer.

R. Salgia, KyungMann Kim, D. Wheeler, 2013, Lung cancer.

Panobinostat, a novel histone deacetylase inhibitor, in advanced medullary and iodine-refractory differentiated thyroid cancer: A Wisconsin Oncology Network trial.

Herb Chen, K. Wisinski, G. Leverson, 2013 .

A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non–small cell lung cancer previously treated with a PD‐1 or PD‐L1 inhibitor: Big Ten Cancer Research Consortium BTCRC‐LUN15‐029

N. Hanna, S. Perkins, A. Traynor, 2022, Cancer.

A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors.

R. Kurzrock, J. Wheler, S. Moulder, 2010 .

Combination therapy with gefitinib and fulvestrant (G/F) for women with non-small cell lung cancer (NSCLC)

J. Siegfried, J. Kolesar, J. Schiller, 2005 .

Gender associations in head and neck squamous cell carcinoma (HNSCC).

P. Harari, Menggang Yu, T. McCulloch, 2012 .

MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Non-Squamous Non-Small Cell Lung Cancer Progressing On/After Checkpoint Inhibitor Therapy or Chemotherapy.

C. Blakely, S. Gadgeel, D. Waterhouse, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Assessment of adherence and relative dose intensity with oral chemotherapy in oncology clinical trials at an academic medical center

G. Wilding, J. Kolesar, K. Wisinski, 2018, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer

G. Wilding, J. Kolesar, J. Eickhoff, 2014, Investigational New Drugs.

A phase I study of R-(-)-gossypol (AT-101) in combination with cisplatin (P) and etoposide (E) in patients with advanced solid tumors and extensive-stage small cell lung cancer (ES-SCLC).

G. Wilding, J. Kolesar, J. Eickhoff, 2010, Journal of Clinical Oncology.